Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

Alkanediols such as 1,6-hexanediol disrupt many phase-separated condensates in cellula and in vitro, but how molecular interactions are perturbed by these compounds remains unclear. This study uses ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

Tda1 protein kinase, activated by Snf1 and yeast GSK3-β, fine-tunes metabolism through the phosphorylation of Hxk2, which is implicated in yeast glucose repression. Tda1 is activated by both Snf1 and ...

Nowadays, the prevalence of sedentary lifestyles and high-caloric diets leads to an imbalance between energy intake and spending. Hence, in the last decades, researchers have observed a significant ...

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS Joenja® is the first and only medicine specifically for APDS to be reimbursed within the ...

A team of Chinese and international scientists has made a groundbreaking advancement in plant genetics by decoding the ...

A study of 634 allergy patients in Tenerife found that 22% were sensitized to edible insects—often without ever consuming ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

Joenja will be the first drug specifically for APDS to be reimbursed within the NHS and is available immediately in England and soon will be in Wales.